Similis Bio | Partnership

Purchase Assets as Needed without
Long Development Timelines

Faster CMC development
Reduced analytical costs
Guaranteed analytical quality

Discuss our data

Full Development with
Flexible Purchase Rights

Optimized process development
Flexible program commitments
Risk mitigated development programs

Book A Consultation

Accelerate Your Highest Value Assets

License vetted biosimilar programs at discrete development stages (i.e. completed cell line or 200L non-GMP production scaled process)
Initiate tech transfer immediately, saving time while increasing your product knowledge concurrently
Jump-start your development years before competition, allowing you to strategically deploy your resources